497 A Study of ALPN-202, a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies

• Kristi Manjarrez,
• Amita Patnaik,
• Meredith McKean,
• Michael Chisamore,
• Nehal Lakhani,
• Hany Zayed,
• Zelanna Goldberg,
• Stanford Peng

Affiliations

Kristi Manjarrez

Aff1 VentiRx Pharmaceuticals Seattle WA USA

Amita Patnaik

3South Texas Accelerated Research Therape, San Antonio, TX, USA

Meredith McKean

Aff6 0000 0001 2291 4776grid.240145.6Division of Cancer MedicineUniversity of Texas MD Anderson Cancer Center 77030 Houston TX USA

Michael Chisamore

2Merch and Co., Inc., Rahway, NJ, USA

Nehal Lakhani

4START Midwest, Grand Rapids, MI, USA

Hany Zayed

1Guy`s and St. Thomas’ NHS Foundation Trust, London, UK

Zelanna Goldberg

Alpine Immune Sciences, Inc., Seattle, WA, USA

Stanford Peng

Alpine Immune Sciences, Inc., Seattle, WA, USA